The RNA Targeting Small Molecule Drug Discovery Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2024-2033).
Learn More On The RNA Targeting Small Molecule Drug Discovery Market:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report
In accordance with The Business Research Company’s illuminating report on RNA Targeting Small Molecule Drug Discovery Global Market for 2024, the landscape has experienced remarkable expansion. The market, valued at $1.45 billion in 2024, is poised to burgeon to $1.78 billion with a robust Compound Annual Growth Rate (CAGR) of 22.3%. This remarkable growth is rooted in an enhanced comprehension of disease genetics, pivotal genomic and proteomic revelations, grappling with drug resistance, substantial investments in biotechnology and pharmaceutical research, coupled with the ascendancy of RNA therapeutics.
Anticipating an astronomical trajectory, the RNA targeting small molecule drug discovery market is projected to soar to $3.97 billion by 2028, driven by a formidable CAGR of 22.2%. This exponential surge is attributed to the broadening scope of RNA epigenetics research, the synergistic impact of RNA-seq and functional genomics, the integration of Artificial Intelligence (AI) into methodologies, the adoption of patient-centric approaches, and the transformative potential of exosome-mediated drug delivery systems. Significant trends in this period encompass the ascendancy of RNA editing technologies, breakthroughs in CRISPR technology, a proliferation of technological innovations, strides in RNA biology, and a spotlight on RNA targeting in neurodegenerative diseases.
The increasing prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market going forward. Cancer is a group of diseases characterized by the uncontrollable growth of cells in the body. Viral infections refer to infections caused by viruses, tiny infectious agents that can only replicate inside the cells of living organisms. RNA targeting-based drug discovery is used to treat cancer, genetic disorders, and viral infections, as these diseases are linked with genes and malfunctioning genetic material, which can be treated using drugs developed using RNA targeting-based methods. For instance, in February 2021, according to the American Cancer Society, a US-based voluntary Health Organization, new cancer cases and cancer deaths number is expected to increase by 47% by 2040, reaching about 28.4 million cases. Furthermore, in 2021, according to the World Health Organization, a Switzerland-based specialized health agency of the United Nations, approximately 38.4 million people were living with HIV, and 650,000 people died due to HIV. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections drives the growth of the RNA-targeted small-molecule drug discovery market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
A discernible trend shaping the landscape is the integration of Artificial Intelligence (AI) in drug discovery within the small-molecule domain. Leading companies are harnessing AI technologies to expedite drug discovery processes, solidifying their foothold in the market. A paradigmatic example is Google Cloud, the cloud computing suite of the esteemed US-based technology giant Google. In May 2024, it unveiled the Target and Lead Identification Suite and Multiomics Suite, empowering the drug discovery continuum. The Multiomics Suite accelerates genetic data identification and analysis, facilitating the design of precision medicines. Simultaneously, the Target and Lead Identification Suite aids researchers in unraveling the intricacies of amino acids and predicting protein structures with unparalleled precision. This strategic amalgamation of advanced technologies not only augments efficiency but also propels the industry towards groundbreaking achievements in small-molecule drug discovery.
The rna targeting small molecule drug discovery market report table of contents includes:
1. Executive Summary
2. RNA Targeting Small Molecule Drug Discovery Market Characteristics
3. RNA Targeting Small Molecule Drug Discovery Market Trends And Strategies
4. RNA Targeting Small Molecule Drug Discovery Market - Macro Economic Scenario
5. Global RNA Targeting Small Molecule Drug Discovery Market Size and Growth
.....
32. Global RNA Targeting Small Molecule Drug Discovery Market Competitive Benchmarking
33. Global RNA Targeting Small Molecule Drug Discovery Market Competitive Dashboard
34. Key Mergers And Acquisitions In The RNA Targeting Small Molecule Drug Discovery Market
35. RNA Targeting Small Molecule Drug Discovery Market Future Outlook and Potential Analysis
36. Appendix
Related Reports:
https://topprnews.com/invert-sugar-market-report/
https://topprnews.com/automotive-48v-system-market-size/
https://topprnews.com/automotive-active-health-monitoring-system-market-report/
https://goodprnews.com/invert-sugar-market-report/
https://goodprnews.com/automotive-48v-system-market-size/
https://goodprnews.com/automotive-active-health-monitoring-system-market-report/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The global Small Molecule Cancer Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
The objectives of this study are to define, segment, and project the size of the Small Molecule Cancer Drug market based on company, product type, end user and key regions.
This report studies the global market size of Small Molecule Cancer Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Small Molecule Cancer Drug in these regions.Report Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of Small Molecule Cancer Drug Market Report This research report categorizes the global Small Molecule Cancer Drug market by top players/brands, region, type and end user.
This report also studies the global Small Molecule Cancer Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:BayerCadila PharmaceuticalAstrazenecaJohnson & JohnsonEli LilyBoehringerRocheMerckNovartisMarket size by Product CytokineHumanized Monoclonal AntibobyOthers Market size by End User LymphomaMyelomaProstate CancerOthers Market size by Region North AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth Africa The study objectives of this report are: To study and analyze the global Small Molecule Cancer Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.To understand the structure of Small Molecule Cancer Drug market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Small Molecule Cancer Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.To project the value and sales volume of Small Molecule Cancer Drug submarkets, with respect to key regions.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Small Molecule Cancer Drug are as follows: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Pcs).
